Published in PLoS One on July 02, 2012
Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One (2012) 0.86
Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci (2015) 0.86
A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. Neuropsychologia (2015) 0.85
The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. Sci Rep (2015) 0.81
Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J Psychiatry (2016) 0.81
Cognitive training with and without additional physical activity in healthy older adults: cognitive effects, neurobiological mechanisms, and prediction of training success. Front Aging Neurosci (2015) 0.78
Independent Associations of Organized Physical Activity and Weight Status with Children's Cognitive Functioning: A Matched-Pairs Design. Pediatr Exerc Sci (2015) 0.77
Neurotrophin levels at admission did not change significantly upon alcohol deprivation and were positively correlated with the BMI and LDL levels. J Mol Psychiatry (2013) 0.75
Gender-specific Associations of the Brain-derived Neurotrophic Factor Val66Met Polymorphism with Neurocognitive and Clinical Features in Schizophrenia. Clin Psychopharmacol Neurosci (2016) 0.75
Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry (2017) 0.75
The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism. Sci Rep (2016) 0.75
Meta-Analysis of BDNF Levels in Autism. Cell Mol Neurobiol (2016) 0.75
Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry (2010) 8.02
Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology (1974) 7.34
The molecular neurobiology of depression. Nature (2008) 6.51
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci (2002) 5.17
Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci (1995) 5.10
Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology (2007) 4.38
Stress and cognitive function. Curr Opin Neurobiol (1995) 4.12
Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry (2008) 4.06
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A (1999) 3.82
BDNF regulates eating behavior and locomotor activity in mice. EMBO J (2000) 3.52
Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A (2004) 3.37
Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res (1996) 3.18
TrkB signalling pathways in LTP and learning. Nat Rev Neurosci (2009) 3.12
BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem (2007) 2.96
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci (2009) 2.40
The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging (2005) 2.39
Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost (2002) 2.16
Neurotrophin regulation of cortical dendritic growth requires activity. Neuron (1996) 2.08
Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res (2005) 1.96
BDNF release from single cells elicits local dendritic growth in nearby neurons. Nat Neurosci (2002) 1.90
Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry (2005) 1.89
Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci (2010) 1.86
Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes (2000) 1.86
Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry (2010) 1.79
Characteristics of BDNF-induced weight loss. Exp Neurol (1995) 1.78
Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord (2008) 1.78
Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem (2006) 1.67
Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol (2006) 1.54
Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry (2010) 1.49
BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology (2004) 1.44
Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol (2006) 1.40
Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology (2010) 1.40
The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol (2011) 1.38
Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett (2006) 1.34
Age-related deficits as working memory load increases: relationships with growth factors. Neurobiol Aging (2002) 1.31
Effects of stress on neurotrophic factor expression in the rat brain. Ann N Y Acad Sci (1995) 1.31
High levels of estrogen enhance associative memory formation in ovariectomized females. Psychoneuroendocrinology (2004) 1.28
Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. Neurosci Res (1997) 1.27
Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology (2005) 1.23
Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol (2009) 1.23
Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet (2004) 1.20
BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Res (1996) 1.12
Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Mol Psychiatry (2003) 1.09
Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol (2005) 1.08
Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur J Neurosci (2002) 1.08
Opposite changes in the serum brain-derived neurotrophic factor in anorexia nervosa and obesity. Psychosom Med (2004) 1.07
BDNF and NGF treatment in lesioned rats: effects on cholinergic function and weight gain. Neuroreport (1992) 1.00
Brain-derived neurotrophic factor, food intake regulation, and obesity. Arch Med Res (2011) 0.98
The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice. Diabetologia (2001) 0.96
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res (2006) 0.94
Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci (2004) 0.92
Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism (2000) 0.88
Diurnal variation and gender differences of plasma brain-derived neurotrophic factor in healthy human subjects. Psychiatry Res (2010) 0.86
Association between brain-derived neurotrophic factor Val66Met and obesity in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83
Reciprocal changes in the expression of neurotrophin mRNAs in target tissues and peripheral nerves of aged rats. Neurosci Lett (1999) 0.81
Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Rev Mol Diagn (2008) 0.81
Special issues in the management of depression in women. Can J Psychiatry (2004) 0.77
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Alzheimer's disease. Lancet (2006) 9.15
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol (2010) 4.78
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans. J Neurosci Methods (2005) 3.32
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry (2006) 2.39
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord (2007) 2.15
The NKI-Rockland Sample: A Model for Accelerating the Pace of Discovery Science in Psychiatry. Front Neurosci (2012) 2.12
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
MRI study of white matter diffusion anisotropy in schizophrenia. Neuroreport (2003) 2.04
Detection of sexual orientation ("gaydar") by homosexual and heterosexual women. Arch Sex Behav (2013) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
The neuropathology and neurobiology of traumatic brain injury. Neuron (2012) 1.99
Reduced frontal white matter integrity in cocaine dependence: a controlled diffusion tensor imaging study. Biol Psychiatry (2002) 1.99
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging (2004) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res (2005) 1.84
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord (2003) 1.77
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet (2002) 1.73
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A (2009) 1.72
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.70
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry (2007) 1.68
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry (2012) 1.67
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents. Am J Psychiatry (2007) 1.61
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol (2013) 1.60
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis (2011) 1.58
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry (2006) 1.57
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am J Ophthalmol (2007) 1.56
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 1.56
Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett (2003) 1.55
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis (2007) 1.54
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry (2009) 1.53
Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg (2012) 1.53